This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
breast-cancer
Breast Cancer
Most common cancer in women; driven by ER/PR hormone signaling, HER2 amplification, and basal TNBC subtypes. BRCA1/2 mutations drive hereditary cases; CDK4/6 inhibitors (palbociclib), anti-HER2 (trastuzumab), PARP inhibitors (olaparib), and immunotherapy are mainstays.
Entry Metadata
| Field | Value |
|---|---|
| ID | breast-cancer |
| Name | Breast Cancer |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. · PubMed 38230766
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792. · PubMed 11248153
- Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925-1936. · PubMed 27959613